Scribe, Jen­nifer Doud­na's newest start­up, nabs a mega-round and a vo­cal in­vestor

Near­ly a decade ago, when the first CRISPR com­pa­nies start­ed look­ing for cap­i­tal, Be­hzad Ag­haz­adeh passed.

Ag­haz­adeh, one of biotech’s more opin­ion­at­ed in­vestors, had in­vest­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER